Orthopedic biotechnology company Ortho Regenerative Technologies focused on developing soft tissue repair regenerative technology in 2020. For 2021, that development is expected to grow.
In 2020, the company's Ortho-R hybrid implant was classified as a biologic drug, according to a March 2 press release. The company also completed four non-brokered private placements and has $2 million cash to fund regulatory- and clinical-stage projects through 2022.
So far this year, Ortho RTI added Patrick O'Donnell, president and CEO of HD LifeSciences, to its board of directors.
Here are some of the company's planned milestones this year:
1. It expects to complete its clinical trial material manufacturing for its Ortho-R cGMP in March.
2. It plans to submit an investigational new drug application for Ortho-R in March and begin enrollment for U.S. trials in the second quarter of 2021.
3. The company wants to select U.S. investment bankers and pursue listing on the Nasdaq stock exchange in the second half of the year.
4. Ortho RTI plans additional partnerships through 2021 and 2022.